

POSTER PRESENTATION

Open Access

48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)

K Arastéh^{1*}, A Ward², A Plettenberg³, JM Livrozet⁴, C Cordes¹, A Winston⁵, E Wang⁶, A Quinson⁶

From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 7-11 November 2010

Background

Wk 24 TRANxITION study data showed patients transitioned from immediate release nevirapine (NVP IR) twice daily (BID) to NVP extended release (NVP XR) once-daily (QD) demonstrated non-inferior efficacy to patients continuing on IR NVP BID [1]. Similar safety was reported for NVP XR and NVP IR in the VERxVE study [2]². Wk 48 efficacy/safety data from TRANxI-TION study are presented here.

Methods

Open label, randomized (2:1), non-inferiority, parallel group study comparing NVP XR 400 mg QD with NVP IR 200 mg BID in HIV-1 patients >18 years receiving IR NVP plus one of three NRTI combinations, with viral load (VL) <50 copies/mL. Patients remained on their previous background therapy for treatment duration. Sustained virologic response (VL <50 copies/mL) was

assessed at Wk 48 using a time-to-loss of virologic response (TLOVR) algorithm.

Results

426 patients completed 48 wks of treatment. 94.9% of NVP XR and 91.9% of NVP IR patients. Mean baseline CD4+ counts: 557.7 cells/mm³ and 569.7 cells/mm³, respectively. 48 Wk data are reported in Table 1. Non-inferiority of virologic suppression was achieved using a TLOVR and snapshot analysis.

Conclusions


At Wk 48, non-inferiority between the NVP XR 400 mg QD and NVP IR 200 mg BID groups was sustained. No unexpected AEs were observed at Wk 48. These data support transition from NVP IR to NVP XR in patients stable on the former formulation.

Table 1

Parameter	NVP XR QD (N=295)	IR NVP BID (N=148)	Difference (95% CI)
Virologic response (VL <50 copies/mL, TLOVR-FAS), n (%)	261 (88.5)	130 (87.8)	0.6 (-5.9, 7.1)*
CD4+ count cells/mm3 (LOCF), mean (SD)	52.1 (140.5)	81.6 (138.2)	-
AEs, n (%)	255 (86.4%)	108 (73.0%)	-
DAIDS Grade 3-4	19 (6.4%)	9 (6.1%)	-
SAEs, n (%)†	30 (10.2%)	12 (8.1%)	-

^{*}Based on Cochran's statistic †None drug related, FAS = full analysis set; AE = adverse event; SAE = Serious adverse event

AEs were mostly mild-moderate in both groups with a higher reported rate of gastrointestinal AEs in XR. The proportion of patients with DAIDS Grade 3/4 AEs was similar in the XR and IR groups.





Author details

¹EPIMED, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany. ²Dupont Circle Physicians Group, Washington DC, USA. ³Asklepios Klinik St. Georg, Hamburg, Germany. ⁴Hôpital Edouard Herriot, Lyon, France. ⁵St Mary's Hospital, Imperial College, London, UK. ⁶Boehringer Ingelheim Inc, Ridgefield Connecticut, USA.

Published: 8 November 2010

References

- 1. Arasteh K, et al., Presented at ICAAC 2010, Boston, USA. Abst: 2148.
- Gathe J, et al., Presented at XVIII International AIDS Conference, Vienna, Austria. Abst: THLBB202.

doi:10.1186/1758-2652-13-S4-P45

Cite this article as: Arastéh et al.: 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANXITION). Journal of the International AIDS Society 2010 13(Suppl 4):P45.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

